The pathophysiological role of dendritic cell subsets in psoriasis

키워드

참고문헌 (103)

1. Christophers, E., "Psoriasis--epidemiology and clinical spectrum", Clin. Exp. Dermatol, 26, pp.314~320 (2001)
2. Lew, W., "Psoriasis genomics: analysis of proinflammatory (type 1) gene expression in large plaque (Western) and small plaque (Asian) psoriasis vulgaris", Br. J. Dermatol, 150, pp.668~676 (2004)
3. Tsai, T. F., "Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan", J. Dermatol. Sci, 63, pp.40~46 (2011)
4. Lowes, M. A., "Pathogenesis and therapy of psoriasis", Nature, 445, pp.866~873 (2007)
5. Davidovici, B. B., "Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions", J. Invest. Dermatol, 130, pp.1785~1796 (2010)
6. Gottlieb, A. B, "Comorbidities in patients with psoriasis", Am. J. Med, 122, pp.1151~1159 (2009)
7. Kim, N., "Comorbidities in psoriasis patients", Semin. Cutan. Med. Surg, 29, pp.10~15 (2010)
8. Ahmed, A., "Quality-of-life effects of common dermatological diseases", Semin. Cutan. Med. Surg, 32, pp.101~109 (2013)
9. Nestle, F. O., "Psoriasis", N. Engl. J. Med, 361, pp.496~509 (2009)
10. Ghoreschi, K., "Immunopathogenesis and role of T cells in psoriasis", Clin. Dermatol, 25, pp.574~580 (2007)
11. Lew, W., "Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression", Trends. Immunol, 25, pp.295~305 (2004)
12. Biedermann, T., "TH1 and TH2 lymphocyte development and regulation of TH cell-mediated immune responses of the skin", J. Investig. Dermatol. Symp. Proc, 9, pp.5~14 (2004)
13. Di Cesare, A., "The IL-23", Th17 axis in the immunopathogenesis of psoriasis, 2009, pp.129, 1339~1350
14. Martin, D. A., "The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings", J. Invest. Dermatol, 133, pp.17~26 (2013)
15. Miossec, P., "Interleukin-17 and type 17 helper T cells", N. Engl. J. Med, 361, pp.888~898 (2009)
16. Weaver, C. T., "The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin", Annu. Rev. Pathol, 8, pp.477~512 (2013)
17. 이영균, "The role of interleukin-17 in bone metabolism and inflammatory skeletal diseases", BMB Reports, 46(10), pp.479~483 (2013), 생화학분자생물학회
18. Lee, E., "Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris", J. Exp. Med, 199, pp.125~130 (2004)
19. Lowes, M. A., "Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells", J. Invest. Dermatol, 128, pp.1207~1211 (2008)
20. Leonardi, C., "Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis", N. Engl. J. Med, 366, pp.1190~1199 (2012)
21. Papp, K. A., "Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis", N. Engl. J. Med, 366, pp.1181~1189 (2012)
22. Bos, J. D., "Predominance of "memory" T cells (CD4+, CDw29+) over "naive" T cells (CD4+, CD45R+) in both normal and diseased human skin", Arch. Dermatol. Res, 281, pp.24~30 (1989)
23. Chang, E. Y., "T-cell activation is potentiated by cytokines released by lesional psoriatic, but not normal, epidermis", Arch. Dermatol, 128, pp.1479~1485 (1992)
24. Banchereau, J, "Dendritic cells and the control of immunity", Nature, 392, pp.245~252 (1998)
25. Steinman, R. M., "Decisions about dendritic cells: past, present, and future", Annu. Rev. Immunol, 30, pp.1~22 (2012)
26. 이미영, "Transcutaneous antigen delivery system", BMB Reports, 46(1), pp.17~24 (2013), 생화학분자생물학회
27. Johnson-Huang, L. M., "Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases", J. Clin. Immunol, 29, pp.247~256 (2009)
28. Zaba, L. C., "Resident and "inflammatory" dendritic cells in human skin", J. Invest. Dermatol, 129, pp.302~308 (2009)
29. Collin, M., "Human dendritic cell subsets", Immunology, 140, pp.22~30 (2013)
30. Romani, N., "Changing views of the role of Langerhans cells", J. Invest. Dermatol, 132, pp.872~881 (2012)
31. Hunger, R. E., "Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T cells", J. Clin. Invest, 113, pp.701~708 (2004)
32. Breathnach, A. S, "Electron Microscopy of Melanocytes and Langerhans Cells in Human Fetal Epidermis at Fourteen Weeks", J. Invest. Dermatol, 44, pp.51~60 (1965)
33. Valladeau, J., "Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules", Immunity, 12, pp.71~81 (2000)
34. Merad, M., "Langerhans cells renew in the skin throughout life under steady-state conditions", Nat. Immunol, 3, pp.1135~1141 (2002)
35. Igyarto, B. Z, "The evolving function of Langerhans cells in adaptive skin immunity", Immunol. Cell Biol, 88, pp.361~365 (2010)
36. Fujita, H., "Human Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-17 production", Proc. Natl. Acad. Sci. U. S. A, 106, pp.21795~21800 (2009)
37. de Jong, A., "CD1a-autoreactive T cells are a normal component of the human alphabeta T cell repertoire", Nat. Immunol, 11, pp.1102~1109 (2010)
38. Seneschal, J., "Human epidermal Langerhans cells maintain immune homeostasis in skin by activating skin resident regulatory T cells", Immunity, 36, pp.873~884 (2012)
39. Zaba, L. C., "Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages", J. Clin. Invest, 117, pp.2517~2525 (2007)
40. Cerio, R., "Characterization of factor XIIIa positive dermal dendritic cells in normal and inflamed skin", Br. J. Dermatol, 121, pp.421~431 (1989)
41. Meunier, L., "Heterogeneous populations of class II MHC+ cells in human dermal cell suspensions. Identification of a small subset responsible for potent dermal antigen- presenting cell activity with features analogous to Langerhans cells", J. Immunol, 151, pp.4067~4080 (1993)
42. Morelli, A. E., "CD4+ T cell responses elicited by different subsets of human skin migratory dendritic cells", J. Immunol, 175, pp.7905~7915 (2005)
43. Mathers, A. R., "Differential capability of human cutaneous dendritic cell subsets to initiate Th17 responses", J. Immunol, 182, pp.921~933 (2009)
44. Furio, L., "Human langerhans cells are more efficient than CD14(-)CD1c(+) dermal dendritic cells at priming naive CD4(+) T cells", J. Invest. Dermatol, 130, pp.1345~1354 (2010)
45. Penel-Sotirakis, K., "Differential capacity of human skin dendritic cells to polarize CD4+ T cells into IL-17, IL-21 and IL-22 producing cells", PLoS One, 7, pp.e45680~ (2012)
46. Haniffa, M., "Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells", Immunity, 37, pp.60~73 (2012)
47. MacDonald, K. P., "Characterization of human blood dendritic cell subsets", Blood, 100, pp.4512~4520 (2002)
48. Bachem, A., "Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells", J. Exp. Med, 207, pp.1273~1281 (2010)
49. Crozat, K., "The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells", J. Exp. Med, 207, pp.1283~1292 (2010)
50. Jongbloed, S. L., "Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens", J. Exp. Med, 207, pp.1247~1260 (2010)
51. Shortman, K, "The CD8+ dendritic cell subset", Immunol. Rev, 234, pp.18~31 (2010)
52. Sancho, D., "Identification of a dendritic cell receptor that couples sensing of necrosis to immunity", Nature, 458, pp.899~903 (2009)
53. Dorner, B. G., "Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells", Immunity, 31, pp.823~833 (2009)
54. Corcoran, L., "The lymphoid past of mouse plasmacytoid cells and thymic dendritic cells", J. Immunol, 170, pp.4926~4932 (2003)
55. Reizis, B., "Plasmacytoid dendritic cells: recent progress and open questions", Annu. Rev. Immunol, 29, pp.163~183 (2011)
56. Siegal, F. P., "The nature of the principal type 1 interferon- producing cells in human blood", Science, 284, pp.1835~1837 (1999)
57. Matta, B. M., "Tolerogenic plasmacytoid DC", Eur. J. Immunol, 40, pp.2667~2676 (2010)
58. Ebner, S., "Expression of C-type lectin receptors by subsets of dendritic cells in human skin", Int. Immunol, 16, pp.877~887 (2004)
59. Lowes, M. A, "Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)", Proc. Natl. Acad. Sci. U. S. A, 102, pp.19057~19062 (2005)
60. Zaba, L. C., "Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses", J. Exp. Med, 204, pp.3183~3194 (2007)
61. Nograles, K. E., "New insights in the immunologic basis of psoriasis", Semin. Cutan. Med. Surg, 29, pp.3~9 (2010)
62. Carragher, D. M., "Ectopic lymphoid tissues and local immunity", Semin. Immunol, 20, pp.26~42 (2008)
63. Morganroth, G. S., "Proliferating cells in psoriatic dermis are comprised primarily of T cells, endothelial cells, and factor XIIIa+ perivascular dendritic cells", J. Invest. Dermatol, 96, pp.333~340 (1991)
64. Guttman-Yassky, E., "Contrasting pathogenesis of atopic dermatitis and psoriasis--part II: immune cell subsets and therapeutic concepts", J. Allergy Clin. Immunol, 127, pp.1420~1432 (2011)
65. Nestle, F. O., "Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines", J. Clin. Invest, 94, pp.202~209 (1994)
66. Miller, G. T., "Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses", J. Exp. Med, 178, pp.211~222 (1993)
67. Ellis, C. N., "Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes", N. Engl. J. Med, 345, pp.248~255 (2001)
68. Chamian, F., "Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris", Proc. Natl. Acad. Sci. U. S. A, 102, pp.2075~2080 (2005)
69. Grakoui, A., "The immunological synapse: a molecular machine controlling T cell activation", Science, 285, pp.221~227 (1999)
70. Lebwohl, M., "A novel targeted T-cell modulator, efalizumab, for plaque psoriasis", N. Engl. J. Med, 349, pp.2004~2013 (2003)
71. Sallusto, F., "The role of chemokine receptors in primary, effector, and memory immune responses", Annu. Rev. Immunol, 18, pp.593~620 (2000)
72. Nickoloff, B. J., "The cytokine and chemokine network in psoriasis", Clin. Dermatol, 25, pp.568~573 (2007)
73. Homey, B., "Chemokines and other mediators as therapeutic targets in psoriasis vulgaris", Clin. Dermatol, 26, pp.539~545 (2008)
74. Mitsui, H., "Combined use of laser capture microdissection and cDNA microarray analysis identifies locally expressed disease-related genes in focal regions of psoriasis vulgaris skin lesions", J. Invest. Dermatol, 132, pp.1615~1626 (2012)
75. Kim, T. G., "Dermal Clusters of Mature Dendritic Cells and T Cells Are Associated with the CCL20", CCR6 Chemokine System in Chronic Psoriasis, 2013, ~
76. Ganguly, D., "Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8", J. Exp. Med, 206, pp.1983~1994 (2009)
77. Wollenberg, A., "Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases", J. Invest. Dermatol, 119, pp.1096~1102 (2002)
78. Gilliet, M., "Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors", Arch. Dermatol, 140, pp.1490~1495 (2004)
79. Nestle, F. O., "Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production", J. Exp. Med, 202, pp.135~143 (2005)
80. Lande, R., "Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide", Nature, 449, pp.564~569 (2007)
81. Chu, C. C., "Harnessing dendritic cells in inflammatory skin diseases", Semin. Immunol, 23, pp.28~41 (2011)
82. Zaba, L. C., "Psoriasis is characterized by accumulation of immunostimulatory and Th1", Th17 cell-polarizing myeloid dendritic cells, 2009, pp.129, 79~88
83. Abrams, J. R., "Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells", J. Exp. Med, 192, pp.681~694 (2000)
84. Nickoloff, B. J., "Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis", Am. J. Pathol, 138, pp.129~140 (1991)
85. Serbina, N. V., "TNF", iNOS-producing dendritic cells mediate innate immune defense against bacterial infection, 2003, pp.19, 59~70
86. Leonardi, C. L., "Etanercept as monotherapy in patients with psoriasis", N. Engl. J. Med, 349, pp.2014~2022 (2003)
87. Nograles, K. E., "Anti-cytokine therapies for psoriasis", Exp. Cell Res, 317, pp.1293~1300 (2011)
88. Annunziato, F., "Phenotypic and functional features of human Th17 cells", J. Exp. Med, 204, pp.1849~1861 (2007)
89. Chan, J. R, "IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis", J. Exp. Med, 203, pp.2577~2587 (2006)
90. Zheng, Y., "Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis", Nature, 445, pp.648~651 (2007)
91. Yawalkar, N., "Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis", J. Dermatol. Sci, 54, pp.99~105 (2009)
92. Fujita, H., "Lesional dendritic cells in patients with chronic atopic dermatitis and psoriasis exhibit parallel ability to activate T-cell subsets", J. Allergy Clin. Immunol, 128, pp.574~582 (2011)
93. Reich, K., "Ustekinumab", Nat. Rev. Drug. Discov, 8, pp.355~356 (2009)
94. Leonardi, C. L., "Efficacy and safety of ustekinumab, a human interleukin-12", 23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double- blind, placebo-controlled trial (PHOENIX 1), 2008, pp.371, 1665~1674
95. Papp, K. A., "Efficacy and safety of ustekinumab, a human interleukin-12", 23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2), 2008, pp.371, 1675~1684
96. Kim, I. H., "Comparative efficacy of biologics in psoriasis: a review", Am. J. Clin. Dermatol, 13, pp.365~374 (2012)
97. Zaba, L. C., "Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis", J. Allergy Clin. Immunol, 125, pp.1261~1268 (2010)
98. Hansel, A., "Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17", TH1 T-cell responses, 2011, pp.127, 787~794
99. Brunner, P. M., "Infliximab induces downregulation of the IL-12", IL-23 axis in 6-sulfo-LacNac (slan)+ dendritic cells and macrophages, 2013, pp.132, 1184~1193
100. Ziegler-Heitbrock, L, "Nomenclature of monocytes and dendritic cells in blood", Blood, 116, pp.e74~e80 (2010)
101. Cros, J., "Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors", Immunity, 33, pp.375~386 (2010)
102. Cumberbatch, M., "Impaired Langerhans cell migration in psoriasis", J. Exp. Med, 203, pp.953~960 (2006)
103. Shaw, F. L., "Langerhans cell mobilization distinguishes between early- onset and late-onset psoriasis", J. Invest. Dermatol, 130, pp.1940~1942 (2010)

관련 논문AI추천